.jetcityimage/iStock Editorial through Getty Images Morgan Stanley has decided on Eli Lilly (NYSE: LLY) as its leading biopharma pick for 2025 as well as measured an additional 9 labels in the space as obese. The financial investment banking company said in a details that it continues to feel “diabesity is readied to end up being.